| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4824b52c88e719bc77147eaae1d0efdd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-201
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2015-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b7ddf990fe6a8c4200894c545292ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55bb3c159c96990e09d61d2329ebd3b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87bc2b93780a807cd4ea97e95d6aca53 |
| publicationDate |
2017-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017023165-A1 |
| titleOfInvention |
Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator |
| abstract |
The present invention relates to a pharmaceutical composition and a therapeutic combination comprising a novel cholesteryl ester transfer protein (CETP) inhibitor and an adenosine triphosphate citrate lyase inhibitor/adenosine monophosphate-activated protein kinase activator, which may be used in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11760714-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110996914-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11744816-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019161307-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11613511-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018218147-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11116739-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11407705-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111971030-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019179494-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022249380-A1 |
| priorityDate |
2015-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |